Evidence map›Paper›PMID 26581144›Full record

Trial reportInternational journal of radiation oncology, biology, physics2015

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.

Suzanne L Wolden, Elizabeth R Lyden, Carola A Arndt, Douglas S Hawkins, James R Anderson, David A Rodeberg, Carol D Morris, Sarah S Donaldson

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suzanne L WoldenDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: woldens@mskcc.org.
Elizabeth R LydenDepartment of Preventive and Societal Medicine, Nebraska Medical Center, Omaha, Nebraska.
Carola A ArndtDepartment of Pediatric and Adolescent Medicine, Mayo Clinic and Foundation, Rochester, Minnesota.
Douglas S HawkinsDivision of Hematology/Oncology, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.
James R AndersonFrontier Science and Technology Research Foundation, Madison, Wisconsin.
David A RodebergDepartment of Surgery, East Carolina University, Greenville, North Carolina.
Carol D MorrisDepartment of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sarah S DonaldsonDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, California.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
INTERGROUP RHABDOMYOSARCOMA STUDYU10CA024507 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI REAMAN, GREGORY H · 1985 to 2002
$2.0M
INTERGROUP RHABDOMYOSARCOMA STUDY STATISTICAL CENTERU10CA072989 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ANDERSON, JAMES R · 1997 to 2002
$1.4M
NCI NIH HHS U10 CA024507NCI NIH HHS U10 CA072989NCI NIH HHS U10CA072989NCI NIH HHS U10 CA098413NCI NIH HHS U10CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U10CA180899NCI NIH HHS U10CA24507
6 · The paper itself

Abstract

purposeTo determine local control according to clinical variables for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group protocol D9803. PATIENTS AND

methodsOf 702 patients enrolled, we analyzed 423 patients with central pathology-confirmed group III embryonal (n=280) or alveolar (group III, n=102; group I-II, n=41) RMS. Median age was 5 years. Patients received 42 weeks of VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (T = topotecan). Local therapy with 50.4 Gy radiation therapy with or without delayed primary excision began at week 12 for group III patients. Patients with group I/II alveolar RMS received 36-41.4 Gy. Local failure (LF) was defined as local progression as a first event with or without concurrent regional or distant failure.

resultsAt a median follow-up of 6.6 years, patients with clinical group I/II alveolar RMS had a 5-year event-free survival rate of 69% and LF of 10%. Among patients with group III RMS, 5-year event-free survival and LF rates were 70% and 19%, respectively. Local failure rates did not differ by histology, nodal status, or primary site, though there was a trend for increased LF for retroperitoneal (RP) tumors (P=.12). Tumors ≥5 cm were more likely to fail locally than tumors <5 cm (25% vs 10%, P=.0004). Almost all (98%) RP tumors were ≥5 cm, with no difference in LF by site when the analysis was restricted to tumors ≥5 cm (P=.86).

conclusionLocal control was excellent for clinical group I/II alveolar RMS. Local failure constituted 63% of initial events in clinical group III patients and did not vary by histology or nodal status. The trend for higher LF in RP tumors was related to tumor size. There has been no clear change in local control over RMS studies, including IRS-III and IRS-IV. Novel approaches are warranted for larger tumors (≥5 cm).

Indexed as

Tumor BurdenAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolCyclophosphamideDactinomycinDisease-Free SurvivalDisease ProgressionFemaleHumansInfantLymph NodesMaleMeningeal NeoplasmsRadiotherapy DosageRetroperitoneal NeoplasmsCyclophosphamideDactinomycinTopotecanVincristine

Identifiers

PMID26581144
PMCPMC5147527

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.